Avacta
AVA6000 set for third dose escalation stageAvacta
FY21 results: a year of frustrations and opportunitiesAvacta
AffiDX LFT sales paused to improve Omicron detectionAvacta
Consumer testing CE mark received for AffiDX LFTAvacta
AVA6000 set to start US Phase I studies in early-2022Avacta
Foundations for two healthy businesses now in placeAvacta
Lead therapeutic asset AVA6000 enters the clinicAvacta
So much more than a play on COVID testing